On March 22, 2022 Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body’s antitumor immunity by altering, or "tuning", immune cells within the tumor microenvironment, reported preclinical results from its PY265 program demonstrating efficacy both as single-agent and in combination with anti-PD1 (Press release, Pionyr Immunotherapeutics, MAR 22, 2022, View Source [SID1234621641]). The latest preclinical research from the program was presented in a poster at the Keystone Symposium titled Cancer Immunotherapy: Decoding the Cancer Immunity Interactome and in a talk today, March 22.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"PY265 further demonstrates our Myeloid Tuning platform by engaging the macrophage receptor, MARCO, to repolarize immunosuppressive myeloid populations in the tumor and induce rapid immune activation," said Kevin P. Baker, Ph.D., SVP and Chief Development Officer at Pionyr. "Our lead programs, PY314 (anti-TREM2) and PY159 (anti-TREM1), are currently in the clinic, and PY265 is on track to complete IND-enabling studies and enter the clinic in 2023."
PY265 targets the macrophage receptor with collagenous structure (MARCO), leveraging a distinct mechanism of action from other myeloid-directed therapeutics currently in development and is expected to be first-in-class. MARCO is expressed on immunosuppressive tumor associated macrophages (TAMs) and monocytic myeloid-derived suppressor cells (mMDSCs), and its expression correlates with aggressive and advanced disease. These subpopulations of tumor myeloid cells are different from those that express the targets of Pionyr’s current lead clinical programs, TREM1 and TREM2. By targeting MARCO, PY265 induces immune activation by reprogramming pro-tumorigenic, M2-like TAMs and mMDSCs to pro-inflammatory macrophages and monocytes, leading to an increase in intra-tumoral infiltration of activated CD8+ T cells and NK cells.
The poster presentation is available on the company website at View Source